Prostate interventions in patients with mild haemophilia: Safe and feasible

Haemophilia ◽  
2021 ◽  
Author(s):  
Benoit Mesnard ◽  
Nicolas Drillaud ◽  
Marianne Sigaud ◽  
Gabriella Hakim ◽  
Samuel Chelly ◽  
...  
Keyword(s):  
Mild Haemophilia

Management of Haemophilia in Sweden

1976 ◽  
Vol 35 (03) ◽  
pp. 510-521 ◽  
Author(s):  
Inga Marie Nilsson
Keyword(s):  
Factor Viii ◽  
Total Population ◽  
Age Groups ◽  
Factor Ix ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Haemophilia B ◽  
Human Fraction ◽  
Mild Haemophilia

SummaryThe incidence of living haemophiliacs in Sweden (total population 8.1 millions) is about 1:15,000 males and about 1:30,000 of the entire population. The number of haemophiliacs born in Sweden in 5-year periods between 1931-1975 (June) has remained almost unchanged. The total number of haemophilia families in Sweden is 284 (77% haemophilia A, 23% haemophilia B) with altogether 557 (436 with A and 121 with B) living haemophiliacs. Of the haemophilia A patients 40 % have severe, 18 % moderate, and 42 % mild, haemophilia. The distribution of the haemophilia B patients is about the same. Inhibitors have been demonstrated in 8% of the patients with severe haemophilia A and in 10% of those with severe haemophilia B.There are 2 main Haemophilia Centres (Stockholm, Malmo) to which haemophiliacs from the whole of Sweden are admitted for diagnosis, follow-up and treatment for severe bleedings, joint defects and surgery. Minor bleedings are treated at local hospitals in cooperation with the Haemophilia Centres. The concentrates available for treatment in haemophilia A are human fraction 1-0 (AHF-Kabi), cryoprecipitate, Antihaemophilic Factor (Hyland 4) and Kryobulin (Immuno, Wien). AHF-Kabi is the most commonly used preparation. The concentrates available for treatment in haemophilia B are Preconativ (Kabi) and Prothromplex (Immuno). Sufficient amounts of concentrates are available. In Sweden 3.2 million units of factor VIII and 1.0 million units of factor IX are given per year. Treatment is free of charge.Only 5 patients receive domiciliary treatment, but since 1958 we in Sweden have practised prophylactic treatment of boys (4–18 years old) with severe haemophilia A. At about 5-10 days interval they receive AHF in amounts sufficient to raise the AHF level to 40–50%. This regimen has reduced severe haemophilia to moderate. The joint score is identical with that found in moderate haemophilia in the same age groups. For treatment of patients with haemophilia A and haemophilia B complicated by inhibitors we have used a large dose of antigen (factor VIII or factor IX) combined with cyclophosphamide. In most cases this treatment produced satisfactory haemostasis for 5 to 30 days and prevented the secondary antibody rise.

Inhibitor to Factor VIII in Mild Haemophilia

1984 ◽  
Vol 52 (01) ◽  
pp. 050-052 ◽  
Author(s):  
P J Kesteven ◽  
L J Holland ◽  
A S Lawrie ◽  
G F Savidge
Keyword(s):  
Factor Viii ◽  
Symptomatic Management ◽  
Viii Inhibitor ◽  
Mild Haemophilia

SummaryFactor VIII inhibitors in mild haemophilia are uncommon and the management of such patients is controversial. The development of a persistently high responding F VIII inhibitor in a mild haemophiliac is reported and the behaviour of the inhibitor discussed in the context of the various therapeutic regimes employed for symptomatic management. When inhibitor titres were low, endogenous F VIII stimulation, by DDAVP, was less immunogenic than the administration of exogenous F VIII concentrates. This inhibitor displayed characteristics of an autoantibody, and was characterised as an immunoglobulin of IgG subtype.

Mild haemophilia A in Iceland: clinical genetic studies of three families with the same mutation

1994 ◽  
Vol 235 (5) ◽  
pp. 443-450 ◽  
Author(s):  
Ó. JENSSON ◽  
S. STENBJERG BERNVIL ◽  
S. JÖNSÖDTTIR ◽  
J. INGERSLEV
Keyword(s):  
Haemophilia A ◽  
Clinical Genetic ◽  
Genetic Studies ◽  
Mild Haemophilia

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements

Haemophilia ◽  
2014 ◽  
Vol 20 (4) ◽  
pp. 550-558 ◽  
Author(s):  
M. Trossaert ◽  
A. Lienhart ◽  
C. Nougier ◽  
M. Fretigny ◽  
M. Sigaud ◽  
...  
Keyword(s):  
Haemophilia A ◽  
Diagnosis And Management ◽  
Mild Haemophilia

A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm

1990 ◽  
Vol 75 (2) ◽  
pp. 217-221 ◽  
Author(s):  
S. A. M. Taylor ◽  
M. B. Liddell ◽  
I. R. Peake ◽  
A. L. Bloom ◽  
D. P. Lillicrap
Keyword(s):  
Cleavage Site ◽  
Factor Ix ◽  
Mild Haemophilia

Fast and Efficient Mutation Detection Method Using Multiplex PCR and Cycle Sequencing

2000 ◽  
Vol 83 (02) ◽  
pp. 244-247 ◽  
Author(s):  
J. M. Costa ◽  
P. Ernault ◽  
D. Vidaud ◽  
M. Vidaud ◽  
D. Meyer ◽  
...  
Keyword(s):  
Multiplex Pcr ◽  
Mutation Detection ◽  
Detection Method ◽  
Deleterious Mutation ◽  
Low Cost ◽  
Detection Methods ◽  
Cycle Sequencing ◽  
Haemophilia B ◽  
Mild Haemophilia

SummaryA method using multiplex PCR followed by cycle-sequencing has been developed to detect mutations in the FIX gene. The procedure was evaluated in 45 severe or mild haemophilia B patients from 45 unrelated families. At least one deleterious mutation was identified in every haemophiliac demonstrating the efficiency of the method. Furthermore the described procedure offers many advantages compared to other screening detection methods: it is fast (less than 48 h), simple (partly automated) and of relatively low cost (it requires only one PCR).

Development of an inhibitor in a man with mild haemophilia A

Haemophilia ◽  
2017 ◽  
Vol 23 (5) ◽  
pp. e473-e474 ◽  
Author(s):  
M. S. Evans ◽  
M. E. Eyster
Keyword(s):  
Haemophilia A ◽  
Mild Haemophilia

DDAVP AND CRYOPRECIPITATE IN MILD HÆMOPHILIA

The Lancet ◽  
1979 ◽  
Vol 314 (8141) ◽  
pp. 535 ◽  
Author(s):  
F.E. Boulton ◽  
A. Smith
Keyword(s):  
Mild Haemophilia

Acute myocardial infarction during substitution with recombinant factor VIII concentrate in a patient with mild haemophilia A

2004 ◽  
Vol 92 (08) ◽  
pp. 425-426 ◽  
Author(s):  
Jean-Louis Kerkhoffs ◽  
Douwe Atsma ◽  
Pranobe Oemrawsingh ◽  
Jeroen Eikenboom ◽  
Felix Van der Meer
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Mild Haemophilia
Sign in / Sign up

Export Citation Format

Share Document